Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity ...

The Government and pharmaceutical giant Eli Lilly, the creator of weight loss drug Mounjaro, are teaming up to explore and ...

The mother's eyes turned yellow among other side effects while on Mounjaro, which had a devastating effect on her gallbladder ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.